Beijing Tong Ren Tang Chinese Medicine Co (HK:3613) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beijing Tong Ren Tang Chinese Medicine Co. has renewed its procurement agreement with Tong Ren Tang Ltd. for Angong Niuhuang Wan Powder, extending the arrangement until mid-2027. This renewal involves connected transactions under Hong Kong’s listing rules, requiring reporting and annual review but not independent shareholder approval. The agreement ensures continued supply of essential raw materials for the company’s production needs, maintaining its market presence.
For further insights into HK:3613 stock, check out TipRanks’ Stock Analysis page.